8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Economic analysis of combination levothyroxine plus liothyronine therapy based on the 1999 Bunevicius trial: cost per QALY modeling, payer coverage barriers, list-price realities, and individual value calculations.
What happened after the landmark 1999 Bunevicius trial ended? This deep dive covers follow-up data, durability of T4+T3 combination benefits, regression-to-mean concerns, and long-term safety signals.
Detailed breakdown of the Bunevicius 1999 trial results comparing T4+T3 combination therapy to T4 monotherapy, including effect sizes, secondary endpoints, and response patterns across cognitive and mood domains.
A deep-dive into pre-specified and post-hoc subgroup analyses from the 1999 Bunevicius NEJM trial, examining which patient groups responded best to T4+T3 combination therapy versus levothyroxine alone, and what that means for clinical decision-making today.
A deep-dive into the 1999 Bunevicius NEJM trial comparing levothyroxine plus liothyronine (T4+T3) to levothyroxine alone for hypothyroidism, covering methodology, results, limitations, and clinical relevance today.
A clinical deep-dive into the real methodological weaknesses, enrollment biases, and generalizability gaps of the 1999 Bunevicius trial comparing T4+T3 combination therapy to T4 monotherapy for hypothyroidism.
A deep-dive into the randomization, blinding, endpoint selection, and statistical approach of the 1999 Bunevicius trial comparing T4/T3 combination therapy to T4 monotherapy for hypothyroidism.
A deep-dive into the 1999 Bunevicius crossover trial of levothyroxine plus liothyronine combination therapy, examining its real clinical implications, guideline responses, and which patients may benefit today.